Skip to main content
PatentCliff

Blue Origin Patent Portfolio

20 US patents · Average 30 claims per patent

D
Patent Strength
39/100
20
Total Patents
30
Avg Claims
2
Expiring in 2 Years
3
Expiring in 5 Years

Technology Focus Areas

Computing & Data ProcessingG06
20 patents
TelecommunicationsH04
20 patents

Patent Details

Patent #TitleGrantedExpiresClaimsStatus
10004940Method for dynamic machine learning inference using CMOSAug 11, 2009Aug 15, 2027271.4y left
10004941Method for configurable machine learning inference using analogJun 12, 2024Jul 7, 20414815.3y left
10004942System for efficient signal transmission in AI-driven networksApr 10, 2005Nov 16, 202223Expired
10004943Apparatus for advanced data encoding in nano-scale systemsNov 3, 2022Oct 25, 20383612.6y left
10004944Apparatus for high-performance data encoding in nano-scale systemsJan 13, 2016May 22, 2033297.1y left
10004945Apparatus for autonomous data encoding in digital systemsMay 8, 2028Feb 28, 20441517.9y left
10004946Computer-implemented method for optimized RF optimizationApr 13, 2002May 16, 202036Expired
10004947Computer-implemented method for enhanced blockchain optimizationAug 18, 2012Nov 28, 2030204.6y left
10004948System for low-latency neural network processing with neuralSep 28, 2010Dec 11, 2027261.7y left
10004949System for integrated neural network processing with nano-scaleDec 19, 2018Aug 25, 2035209.4y left
10004950Apparatus for autonomous data encoding in analog systemsJun 16, 2017Jan 28, 2034357.8y left
10004951System for low-latency signal transmission in CMOS networksJun 6, 2024Mar 16, 20414214.9y left
10004952Computer-implemented method for low-latency neural optimizationApr 16, 2025Jul 19, 20433117.3y left
10004953Method for optimized channel estimation in cloud communicationsDec 10, 2028May 9, 20444118.1y left
10004954Method for scalable channel estimation in MEMS communicationsSep 11, 2027Feb 5, 20433416.8y left
10004955Method for low-latency channel estimation in graphene communicationsDec 12, 2026Oct 18, 20432817.5y left
10004956Apparatus for low-latency data encoding in 5G systemsJun 28, 2019Jun 26, 2036510.2y left
10004957Method for configurable machine learning inference using AI-drivenMar 22, 2022Feb 22, 20391712.9y left
10004958System for enhanced signal transmission in digital networksOct 4, 2017Jul 19, 2034418.3y left
10004959Apparatus for high-performance data encoding in cloud systemsMay 26, 2024Aug 4, 20424816.3y left

Related Patent Portfolios

IBM

150 patents · Strength: B

Samsung

130 patents · Strength: C

Canon

90 patents · Strength: C

Microsoft

100 patents · Strength: C

Frequently Asked Questions

Blue Origin holds 20 US patents with an average of 30 claims per patent. The portfolio has a Patent Strength Score of 39/100 (Grade D).

Blue Origin has 2 patents expiring within 2 years and 3 patents expiring within 5 years. These expirations may create opportunities for competitors and generic entrants.

Blue Origin's key technology focus areas include Computing & Data Processing, Telecommunications. The portfolio spans 2 distinct technology classifications (CPC codes).

The Patent Strength Score (0-100, A-F) benchmarks a company's patent portfolio quality based on portfolio size (30%), claims breadth (25%), time remaining to expiration (25%), and portfolio diversity across technology areas (20%).

Last updated:

Patent Strength Score is based on portfolio size, claims breadth, time to expiration, and technology diversity using CPC classifications.

The this entity record above pulls directly from the FDA Orange Book and USPTO patent records. What follows is the per-entity context — how this entity sits in the broader U.S. pharmaceutical patent expirations distribution and which underlying factors drive the headline numbers.

Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.

Source: USPTO patent search, 2026.